These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 17964998)

  • 1. [Angiogenesis targeting in gastro-intestinal cancers].
    Meric JB
    Bull Cancer; 2007; 94(7 Suppl):F207-15. PubMed ID: 17964998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current role of bevacizumab in colorectal cancer.
    Saltz L
    Clin Adv Hematol Oncol; 2009 Jun; 7(6):375-6. PubMed ID: 19606071
    [No Abstract]   [Full Text] [Related]  

  • 3. Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.
    Duffy A; Shia J; Huitzil-Melendez FD; Fong Y; O'Reilly EM
    Clin Colorectal Cancer; 2008 Mar; 7(2):140-3. PubMed ID: 18501074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Advances in the treatment of metastatic colorectal cancer with bevacizumab].
    Longo F; Mansueto G
    Tumori; 2006; 92(5):suppl 1-12. PubMed ID: 17168449
    [No Abstract]   [Full Text] [Related]  

  • 5. Perforating dermatosis in a patient receiving bevacizumab.
    Vano-Galvan S; Moreno C; Medina J; Pérez-García B; García-López JL; Jaén P
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):972-4. PubMed ID: 19470057
    [No Abstract]   [Full Text] [Related]  

  • 6. The treatment of colorectal carcinoma: standard chemotherapy and beyond.
    Eng C; Abbruzzese JL
    Clin Adv Hematol Oncol; 2004 Sep; 2(9):592-8. PubMed ID: 16163242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bevacizumab in the treatment of colorectal carcinoma: news from ASCO 2008].
    Mansueto G; Longo F
    Tumori; 2008; 94(4):suppl 1-14. PubMed ID: 18822711
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab.
    Finn RS; Zhu AX
    Expert Rev Anticancer Ther; 2009 Apr; 9(4):503-9. PubMed ID: 19374603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
    Jary M; Borg C; Bouché O; Kim S; André T; Bennouna J
    Bull Cancer; 2015 Sep; 102(9):758-71. PubMed ID: 26232849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.
    Hurwitz H; Kabbinavar F
    Oncology; 2005; 69 Suppl 3():17-24. PubMed ID: 16301832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of the role of angiogenesis as a chemotherapeutic target.
    Chu E
    Clin Colorectal Cancer; 2003 Aug; 3(2):74-5. PubMed ID: 12952560
    [No Abstract]   [Full Text] [Related]  

  • 12. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
    Dohn LH; Jensen BV; Larsen FO
    Acta Oncol; 2010 Apr; 49(3):395-6. PubMed ID: 20001495
    [No Abstract]   [Full Text] [Related]  

  • 13. First description of an uterine perforation potentially imputable to treatment with bevacizumab.
    Uguen T; Leconte B; Desgrippes R; Tchoundeu B; Bretagne JF; Manfredi S
    Acta Oncol; 2012 Nov; 51(8):1102-4. PubMed ID: 23020310
    [No Abstract]   [Full Text] [Related]  

  • 14. [Antiangiogenic therapy for gastrointestinal tumors].
    Lakatos G; Tulassay Z
    Orv Hetil; 2008 Dec; 149(49):2317-24. PubMed ID: 19042183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab in the treatment of colorectal cancer.
    Marshall JL
    Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):8-9. PubMed ID: 17491585
    [No Abstract]   [Full Text] [Related]  

  • 16. The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer.
    Malik Z; Eng C
    Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):4-7. PubMed ID: 17491584
    [No Abstract]   [Full Text] [Related]  

  • 17. Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer.
    Jackson C; Cunningham D
    Eur J Cancer; 2008 Mar; 44(5):652-62. PubMed ID: 18313913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The development of bevacizumab in noncolorectal gastrointestinal malignancies: gastroesophageal, pancreatic, and hepatocellular carcinoma.
    Shah MA
    Clin Adv Hematol Oncol; 2014 Apr; 12(4):239-46. PubMed ID: 25003353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The future development of bevacizumab in colorectal cancer.
    Díaz-Rubio E; Schmoll HJ
    Oncology; 2005; 69 Suppl 3():34-45. PubMed ID: 16301834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of bevacizumab for advanced colorectal cancer].
    Naito M; Hoshino S; Noda N; Nakano M; Matsuo K; Yamauchi Y; Shinohara T; Tanaka S; Yamashita Y
    Gan To Kagaku Ryoho; 2010 Jan; 37(1):83-8. PubMed ID: 20087037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.